Communiqués de presse Archive - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Communiqués de presse Archive - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s

May 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
May 2025

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
May 2025

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
April 2025

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
April 2025

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
April 2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
April 2025

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
March 2025

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
March 2025

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
March 2025

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 21
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris